Fresh off one of its best wins of the season, the Oklahoma City Thunder will face off against the Miami Heat at home tonight. The Thunder needed a 21-point comeback to down the Memphis Grizzlies days ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why. Researchers found that inflammation in the brain disrupts the energy supply of ...

Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been able to identify two biologically distinct types of multiple sclerosis (MS), ...

Among multiple sclerosis (MS) patients, those with a high relative abundance of Fusobacterium nucleatum together with other periodontal bacteria were more likely to have moderate to severe disability ...

A study from Sweden’s Uppsala University discovered a link between microplastics and multiple sclerosis (MS). The research, published in the journal Environmental International, discovered that ...

Shares drop after FDA delays decision on tolebrutinib drug Late-stage trial shows drug fails to slow disability progression Analysts fret over Sanofi drug pipeline and investor confidence Dec 15 ...

People with multiple sclerosis (MS) who have higher levels of Fusobacterium nucleatum in the mouth — bacteria that can contribute to periodontitis, a serious gum infection — may be more likely to ...

Ned Fulmer is sharing insight into a personal challenge. The former Try Guys member revealed he’s been quietly battling multiple sclerosis (MS)—a disease in which the body’s immune system mistakenly ...

Selma Blair is grateful to be feeling good. The Cruel Intentions star, who shared her multiple sclerosis (MS) diagnosis in 2018, offered a positive update on her health, revealing that she’s been ...

Selma Blair shared an update on her battle with multiple sclerosis (MS), more than seven years after revealing her diagnosis. Speaking to Stellar on Saturday, November 22, Blair, 53, confirmed she had ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...